Evidence based guidelines for treatment of physical symptoms during the last days of life in older people are not available.
Aim:
We wanted to synthesize the existing evidence on the pharmacological treatment of pain, dyspnea, death rattle, fever, nausea, and vomiting during the last days of life in older people to develop recommendations that can help guide clinical practice.
Design:
A systematic review was conducted (PROSPERO #CRD42023406100) and reported in accordance with PRISMA guidelines.
Data sources:
MEDLINE and EMBASE were searched from inception till March 2023, together with national and international guideline databases.
Results:
Four predominantly descriptive studies on opioid use were included for the treatment of pain and four for dyspnea, without clear evidence for the choice of one specific opioid, nor a specific opioid dose. For death rattle, five randomized controlled trials and two retrospective studies were included. These provide evidence for the prophylactic treatment of death rattle with hyoscine butylbromide. For fever, nausea, and vomiting, no articles met the inclusion criteria.
Conclusion:
Limited evidence exists to guide the pharmacological treatment of pain, dyspnea, death rattle, fever, nausea, and vomiting in the last days of life of older people. Other than the use of opioids for treatment of pain and dyspnea and prophylactic administration of hyoscine butylbromide to decrease the likelihood of developing death rattle, no specific recommendations can be formulated for use in clinical practice. This demonstrates the challenging nature of research in the last days of life of older people, despite its pressing need.
KlapwijkMSCaljouwMAVan Soest-PoortvlietMC, et al. Symptoms and treatment when death is expected in dementia patients in long-term care facilities. BMC Geriatr2014; 14: 99.
2.
HendriksSASmalbruggeMGalindo-GarreF, et al. From admission to death: prevalence and course of pain, agitation, and shortness of breath, and treatment of these symptoms in nursing home residents with dementia. J Am Med Dir Assoc2015; 16(6): 475–481.
3.
KoppitzABosshardGSchusterDH, et al. Type and course of symptoms demonstrated in the terminal and dying phases by people with dementia in nursing homes. Z Gerontol Geriatr2015; 48(2): 176–183.
4.
PivodicLSmetsTVan den NoortgateN, et al. Quality of dying and quality of end-of-life care of nursing home residents in six countries: an epidemiological study2018; 32(10): 1584–1595.
5.
MahKSwamiNPopeA, et al. Caregiver bereavement outcomes in advanced cancer: associations with quality of death and patient age. Support Care Cancer2022; 30(2): 1343–1353.
6.
National Institute for health and Care Excellence. Care of dying adults in the last days of life. Online Referencing. https://www.nice.org.uk/guidance/ng31. (2015, accessed 18 October, 2023).
7.
CrawfordGBDzierzanowskiTHauserK, et al. Care of the adult cancer patient at the end of life: ESMO clinical practice guidelines. ESMO Open2021; 6(4): 100225.
HoninxEVan DopNSmetsT, et al. Dying in long-term care facilities in Europe: the PACE epidemiological study of deceased residents in six countries. BMC Public Health2019; 19(1): 1199.
10.
GnjidicDJohnellK.Clinical implications from drug-drug and drug-disease interactions in older people. Clin Exp Pharmacol Physiol2013; 40(5): 320–305.
11.
EdwinaAEDiaNDreesenE, et al. Insights into the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in older adults with atrial fibrillation: a structured narrative review. Clin Pharmacokinet2023; 62(3): 351–373.
12.
OngTThiamCN.Special consideration for pain management in the older person. Clin Med2022; 22(4): 295–297.
13.
TangheMVan Den NoortgateNPivodicL, et al. Opioid, antipsychotic and hypnotic use in end of life in long-term care facilities in six European countries: results of PACE. Eur J Public Health2019; 29(1): 74–79.
14.
JanssensWHVan Den NoortgateNPiersRD.Pharmacological treatment in the dying geriatric patient: describing use and dosage of opioids in the acute geriatric wards and palliative care units of three hospitals. Eur Geriatr Med2021; 12(3): 545–550.
15.
TangheMVan Den NoortgateNDeliensL, et al. Opioid underuse in terminal care of long-term care facility residents with pain and/or dyspnoea: a cross-sectional PACE-survey in six European countries. Palliat Med2020; 34(6): 784–794.
16.
Brisbane South Palliative Care Collaborative. Guide to the pharmacological management of end of life (terminal) symptoms in residential aged care residents: a resource for general practitioners. Brisbane: State of Queensland (Queensland Health), 2015.
17.
SeahSTALowJAChanYH. Symptoms and care of dying elderly patients in an acute hospital. Singapore Med J2005; 46(5): 210–214.
18.
RodriguezKLHanlonJTSubashanP, et al. A cross-sectional analysis of the prevalence of undertreatment of nonpain symptoms and factors associated with undertreatment in older nursing home hospice/palliative care patients. Am J Geriatr Pharmacother2010; 8(3): 225–232.
19.
Werkgroep ontwikkeling richtlijnen eerste lijn (WOREL). Leidraad richtlijnontwikkeling, 2020.
20.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
21.
HongQNPluyePFàbreguesS, et al. Mixed Methods Appraisal Tool (MMAT), version 2018. Canadian Intellectual Property Office, Industry Canada.
22.
FürstPLundströmSKlepstadP, et al. Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center. BMC Palliat Care2020; 19(1): 172.
23.
GolčićMDobrila-DintinjanaRGolčićG, et al. Differences between transdermal fentanyl and buprenorphine in the elderly hospice patients. Pain Res Treat2018; 2018: 8610538.
24.
GolčićMDobrila-DintinjanaRGolčićG, et al. Should we treat pain in the elderly palliative care cancer patients differently?Acta Clin Croat2020; 59(3): 387–393.
25.
RashidiNMZordanRDFlynnE, et al. The care of the very old in the last three days of life. J Palliat Med2011; 14(12): 1339–1344.
26.
Benítez-RosarioMARosa-GonzálezIGonzález-DávilaE, et al. Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients. Support Care Cancer2019; 27(1): 157–164.
27.
MatsudaYMaedaITachibanaK, et al. Low-dose morphine for dyspnea in terminally ill patients with idiopathic interstitial pneumonias. J Palliat Med2017; 20(8): 879–883.
28.
MoriMKawaguchiTImaiK, et al. How successful is parenteral oxycodone for relieving terminal cancer dyspnea compared with morphine? A multicenter prospective observational study. J Pain Symptom Manage2021; 62(2): 336–345.
29.
HugelHEllershawJGamblesM.Respiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide. J Palliat Med2006; 9(2): 279–284.
WildiersHDhaenekintCDemeulenaereP, et al. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage2009; 38(1): 124–133.
32.
MercadanteSMarinangeliFMaseduF, et al. Hyoscine butylbromide for the management of death rattle: sooner rather than later. J Pain Symptom Manage2018; 56(6): 902–907.
33.
ClarkKCurrowDCAgarM, et al. A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life. J Pain Palliat Care Pharmacother2008; 22(2): 131–138.
34.
HeislerMHamiltonGAbbottA, et al. Randomized double-blind trial of sublingual atropine vs. Placebo for the management of death rattle. J Pain Symptom Manage2013; 45(1): 14–22.
35.
van EschHJvan ZuylenLGeijtemanECT, et al. Effect of prophylactic subcutaneous scopolamine butylbromide on death rattle in patients at the end of life: the SILENCE randomized clinical trial. JAMA2021; 326(13): 1268–1276.
36.
van EschHJvan ZuylenLOomen-de HoopE, et al. Scopolaminebutyl given prophylactically for death rattle: study protocol of a randomized double-blind placebo-controlled trial in a frail patient population (the SILENCE study). BMC Palliat Care2018; 17(1): 105.
37.
SteinhauserKEChristakisNAClippEC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA2000; 284(19): 2476–2482.
38.
MeierEAGallegosJVThomasLP, et al. Defining a good death (successful dying): literature review and a call for research and public dialogue. Am J Geriatr Psychiatry2016; 24: 261–271.
39.
BercovitchMWallerAAdunskyA.High dose morphine use in the hospice setting: A database survey of patient characteristics and effect on life expectancy. Cancer1999; 86(5): 871–877.
40.
HallSGallagherRMGracelyE, et al. The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose. Pain Med2003; 4(2): 125–134.
41.
DavisMPGlarePQuigleyC, et al. Opioids in cancer pain. 2nd ed.New York: Oxford University Press, 2009.
42.
HiasJvan der LindenLWalgraeveK, et al. Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians. Br J Clin Pharmacol2022; 88(3): 1020–1030.
43.
FrankenLGMasmanADde WinterBCM, et al. Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill adult patients. Clin Pharmacokinet2016; 55(6): 697–709.
44.
FrankenLGde WinterBCMvan EschHJ, et al. Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol. Expert Opin Drug Metab Toxicol2016; 12(6): 669–680.
45.
JansenKHaugenDFPontL, et al. Safety and effectiveness of palliative drug treatment in the last days of life-a systematic literature review. J Pain Symptom Manage2018; 55(2): 508–521.
46.
van DijkJFMZaslanskyRvan BoekelRLM, et al. Postoperative pain and age: a retrospective cohort association study. Anesthesiology2021; 135(6): 1104–1119.
47.
BeachPAHumbelADietrichMS, et al. A cross-sectional study of pain sensitivity and unpleasantness in people with vascular dementia. Pain Med2022; 23(7): 1231–1238.
48.
AndersonARIversenWLCarterMA, et al. Experimentally evoked pain in Alzheimer’s disease. J Am Assoc Nurse Pract2021; 34(1): 18–25.
49.
van der SteenJTSampsonELvan den BlockL, et al. Tools to assess pain or lack of comfort in Dementia: a content analysis. J Pain Symptom Manage2015; 50(5): 659–675.
50.
KlapwijkMSCaljouwMAAvan Soest-PoortvlietMC, et al. Symptoms and treatment when death is expected in dementia patients in long-term care facilities. BMC Geriatr2014; 14(1): 1–8.
51.
HuiDMaddocksMJohnsonMJ, et al. Management of breathlessness in patients with cancer: ESMO Clinical Practice Guidelines. ESMO Open2020; 5(6): e001038.
52.
EkströmMBajwahSBlandJM, et al. One evidence base; three stories: do opioids relieve chronic breathlessness. Thorax2018; 73(1): 88–90.
53.
LindqvistOLundquistGDickmanA, et al. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion. J Palliat Med2013; 16(1): 38–43.
54.
BrownCEJeckerNSCurtisJR. Inadequate palliative care in chronic lung disease. An issue of health care inequality. Ann Am Thorac Soc2016; 13(3): 311–316.
55.
ZerzanJLeeCAHaverhalsLH, et al. Exploring physician decisions about end-of-life opiate prescribing: a qualitative study. J Palliat Med2011; 14(5): 567–572.
56.
HughesAWilcockACorcoranR, et al. Audit of three antimuscarinic drugs for managing retained secretions. Palliat Med2000; 14(3): 221–222.
57.
BackINJenkinsKBlowerA, et al. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliat Med2001; 15: 329–336.
58.
van EschHJCampbellMLMoriM, et al. Should (prophylactic) medications be used for the management of death rattle?J Pain Symptom Manage2023; 66(4): 513–517.
59.
HirschCAMarriottJFFaullCM.Influences on the decision to prescribe or administer anticholinergic drugs to treat death rattle: a focus group study. Palliat Med2013; 27(8): 732–738.
60.
MoonsLDe RooMLDeschodtM, et al. Death Rattle: current experiences and non-pharmacological management – A narrative review. Ann Palliat Med2024; 13: 150–161.
61.
El KhouryJHlaisSHelouM, et al. Evaluation of efficacy and safety of subcutaneous acetaminophen in geriatrics and palliative care (APAPSUBQ). BMC Palliat Care2022; 21(1): 42.
BachertCChuchalinAGEisebittR, et al. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study. Clin Ther2005; 27(7): 993–1003.
64.
SandeTALairdBJAFallonMT.The management of opioid-induced nausea and vomiting in patients with cancer: a systematic review. J Palliat Med2019; 22(1): 90–97.
65.
FriedLPTangenCMWalstonJ.Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci2001; 56(3): 146–156.
66.
CleggAYoungJIliffeS, et al. Frailty in elderly people. Lancet2013; 381(9868): 752–762.
67.
StrandbergTEPitkalaKHTilvisRS.Predictors of mortality in home-dwelling patients with cardiovascular disease aged 75 and older. J Am Geriatr Soc2009; 57(2): 279–284.
68.
ThomasKSOgarekJATenoJM, et al. Development and validation of the nursing home minimum data set 3.0 mortality risk score (MRS3). J Gerontol A Biol Sci Med Sci2019; 74(2): 219–225.
69.
OuchiKStroutTHaydarS, et al. Association of emergency clinicians’ assessment of mortality risk with actual 1-month mortality among older adults admitted to the hospital. JAMA Netw Open2019; 2(9): e1911139.
70.
van EschHJPrinsSDvan de VathorstS, et al. Reflections on including patients in a randomized placebo-controlled multicentre trial in the dying phase – the SILENCE study. J Pain Symptom Manage2022; 63(5): e545–e552.
71.
CarpenterJGUlrichCHodgsonN, et al. Alternative consent models in pragmatic palliative care clinical trials. J Pain Symptom Manage2021; 62(1): 183–191.
72.
KarsMCvan ThielGJMWvan der GraafR, et al. A systematic review of reasons for gatekeeping in palliative care research. In Palliat Med2016; 30(6): 533–548.
73.
VlckovaKPolakovaKTuckovaA, et al. Views of patients with advanced disease and their relatives on participation in palliative care research. BMC Palliat Care2021; 20(1): 80.
74.
BloomerMJHutchinsonAMBrooksL, et al. Dying persons’ perspectives on, or experiences of, participating in research: an integrative review. Palliat Med2018; 32(4): 851–860.
75.
van EschHJStoppelenburgAvan ZuylenL, et al. When a dying patient is asked to participate in a double-blind, placebo-controlled clinical trial on symptom control: the decision-making process and experiences of relatives. Palliat Med2022; 36(10): 1552–1558.
76.
LamHRChowSTaylorK, et al. Challenges of conducting research in long-term care facilities: a systematic review. BMC Geriatr2018; 18(1): 242.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
